Doug Roeder
General Partner @ Delphi Ventures
San Mateo, United States
Doug Roeder is a General Partner at Delphi Ventures. Doug holds an AB from Dartmouth College.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Doug Roeder invests in
Stages Doug Roeder invests in
Countries Doug Roeder invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 9 (64%)
- Medical Device 9 (64%)
- Biotechnology 5 (36%)
- Medical 3 (21%)
- Health Diagnostics 2 (14%)
Stage
- Series D 4 (29%)
- Series E 2 (14%)
- Funding Round 2 (14%)
- Series A 1 (7%)
- Series B 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $20M / Venture - Series Unknown / Apr 08, 2015 | ||
| Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $25M / Series B / Sep 23, 2014 | ||
| EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $18.7M / Jul 01, 2014 | ||
| Senseonics is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that is intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. | $20M / Jun 05, 2014 | ||
| Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $14M / Series B / Jan 13, 2014 | ||
| TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $40M / Series E / Nov 18, 2013 | ||
| Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development forthe treatment of other debilitating diseases within ophthalmology. | $27M / Series B / Jan 31, 2013 | ||
| Labcyte Inc. is a laboratory instrumentation company with a novel approach to dispensing small volumes of liquids for life sciences applications. The company's acoustic dispensing technology uses a focused beam of acoustic energy to eject nanoliter-scale droplets of fluid from one plate to another, with high accuracy atlow volumes and reduced consumables costs. In addition to DBL Investors, investors include Alloy Ventures, Abingworth, New Leaf Venture Partners, and Cross Atlantic Partners.Labcyte was founded in 2000 and is based in San Jose, California, United States. | $5.3M / Series D / Jan 08, 2013 | ||
| Tandem diabetes care provides products that empower both people with diabetes and those who care for them. It offers diabetic insulin pumps for adults and children to diabetes needs, including keeping blood glucose levels within target ranges. | $36.4M / Series D / Sep 11, 2012 | ||
| TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $60M / Series D / Jun 04, 2012 | ||
| See all 14 investments → | |||
Co-Investors
About Delphi Ventures
Delphi Ventures is a venture capital firm that has focused on investing in biotechnology and medical devices for over two decades. With more than $1.1 billion in committed capital, Delphi Ventures has funded over 170 companies. More than 110 of our portfolio companies have either completed an initial public offering or have been acquired by a leading healthcare corporation.
Delphi Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James Bochnowski
Founder & Managing Member
|
|||
Matthew T. Potter
CFO| Partner
|
|||
David L. Douglass
General Partner
|
|||
Deepika R Pakianathan
General Partner
|
|||
|
Doug Roeder
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Doug Roeder invest in?
Doug Roeder invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series D and Series E stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Doug Roeder?
Public channels for Doug Roeder include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Doug Roeder last invest?
The most recent investment recorded for Doug Roeder closed in Apr 2015. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
